Publications by authors named "Juan Julio Kassack Ipina"
Article Synopsis
- Metformin shows potential as an adjunctive treatment for Acute Lymphoblastic Leukemia (ALL), enhancing the cancer-fighting effects of chemotherapy.
- A study involving 123 patients revealed that those treated with metformin experienced a lower relapse rate (6.5%) compared to those receiving standard chemotherapy alone (17.1%).
- Overall survival and disease-free survival rates were 43% and 47%, respectively, indicating that metformin might improve outcomes for ALL patients regardless of their initial biological risk.
Background: In acute lymphoblastic leukemia (ALL), high ABCB1 gene expression has been associated with treatment resistance, which affects patient prognosis. Many preclinical reports and retrospective population studies have shown an anti-cancer effect of metformin. Therefore, the objective of this study was to assess the effect of metformin on the treatment regimen in patients with ALL who exhibited high levels of ABCB1 gene expression and to determine its impact on overall survival.
View Article and Find Full Text PDF[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Rev Peru Med Exp Salud Publica
December 2016
Article Synopsis
- A retrospective study assessed the mortality and toxicity of the Hyper-CVAD protocol as a first-line treatment for acute lymphoblastic leukemia in patients under 40, comparing it to the HGMLAL07 regimen.
- Results showed that the Hyper-CVAD regimen had lower complete remission rates (67.7% vs. 81.9%) and survival rates at one year (40% vs. 62%) and two years (18% vs. 34%).
- The study suggests that due to its high cost and toxicity, Hyper-CVAD should primarily be used for patients with relapsed or refractory leukemia.
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259) or imatinib 400 mg (n = 260) once daily. Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
View Article and Find Full Text PDF